Enlivex Current Ratio vs Free Cash Flow per Share Analysis

ENLV Stock

USD 1.27 0.05 3.79%

Enlivex Therapeutics financial indicator trend analysis is much more than just examining Enlivex Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enlivex Therapeutics is a good investment. Please check the relationship between Enlivex Therapeutics Current Ratio and its Free Cash Flow Per Share accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

Current Ratio vs Free Cash Flow Per Share

Current Ratio vs Free Cash Flow per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enlivex Therapeutics Current Ratio account and Free Cash Flow per Share. At this time, the significance of the direction appears to have no relationship.

The correlation between Enlivex Therapeutics' Current Ratio and Free Cash Flow per Share is 0.04. Overlapping area represents the amount of variation of Current Ratio that can explain the historical movement of Free Cash Flow per Share in the same time period over historical financial statements of Enlivex Therapeutics, assuming nothing else is changed. The correlation between historical values of Enlivex Therapeutics' Current Ratio and Free Cash Flow per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Ratio of Enlivex Therapeutics are associated (or correlated) with its Free Cash Flow per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow per Share has no effect on the direction of Current Ratio i.e., Enlivex Therapeutics' Current Ratio and Free Cash Flow per Share go up and down completely randomly.

Correlation Coefficient

0.04

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Current Ratio

A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Most indicators from Enlivex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enlivex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.Selling General Administrative is likely to climb to about 8.1 M in 2024, despite the fact that Tax Provision is likely to grow to (3.4 K).

Enlivex Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Accounts Payable	Cash	Other Assets	Short Term Investments	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Treasury Stock	Long Term Debt	Good Will	Preferred Stock Total Equity	Other Liab	Net Debt	Retained Earnings	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets
Total Assets		0.48	0.75	1.0	0.73	0.5	0.47	0.64	-0.09	0.81	0.6	0.47	0.37	0.03	0.56	0.57	-0.56	0.8	-0.32	-0.23	0.63	0.31	0.41	0.47	0.42	0.62
Other Current Liab	0.48		0.88	0.43	0.24	0.2	0.61	0.52	-0.32	0.81	0.05	0.85	0.7	0.52	-0.08	0.13	0.08	0.66	-0.15	-0.71	0.51	0.67	0.88	0.84	0.71	0.51
Total Current Liabilities	0.75	0.88		0.71	0.56	0.46	0.69	0.47	-0.3	0.91	0.34	0.7	0.61	0.34	0.26	0.32	-0.26	0.74	-0.34	-0.53	0.54	0.57	0.7	0.69	0.59	0.55
Total Stockholder Equity	1.0	0.43	0.71		0.75	0.48	0.44	0.63	-0.07	0.77	0.63	0.41	0.33	0.01	0.6	0.6	-0.6	0.78	-0.29	-0.18	0.59	0.26	0.36	0.41	0.37	0.58
Accounts Payable	0.73	0.24	0.56	0.75		0.49	0.52	0.08	-0.1	0.46	0.7	0.05	0.32	0.01	0.65	0.69	-0.65	0.53	-0.28	-0.05	0.09	-0.08	0.02	0.06	0.13	0.19
Cash	0.5	0.2	0.46	0.48	0.49		0.51	-0.08	-0.26	0.59	0.11	0.29	0.31	-0.25	0.17	0.07	-0.17	0.42	-0.96	-0.2	0.41	0.02	0.22	0.3	0.33	0.42
Other Assets	0.47	0.61	0.69	0.44	0.52	0.51		0.07	-0.48	0.62	0.35	0.54	0.89	0.59	0.2	0.37	-0.2	0.78	-0.36	-0.66	0.18	-0.06	0.52	0.56	0.55	0.17
Short Term Investments	0.64	0.52	0.47	0.63	0.08	-0.08	0.07		0.09	0.64	0.05	0.68	0.29	0.28	-0.03	0.09	0.03	0.62	0.1	-0.41	0.82	0.61	0.66	0.67	0.61	0.76
Other Current Assets	-0.09	-0.32	-0.3	-0.07	-0.1	-0.26	-0.48	0.09		-0.29	-0.1	-0.16	-0.33	-0.19	-0.05	-0.13	0.05	-0.31	0.22	0.41	-0.01	-0.16	-0.13	-0.17	-0.29	0.03
Total Liab	0.81	0.81	0.91	0.77	0.46	0.59	0.62	0.64	-0.29		0.16	0.82	0.62	0.25	0.1	0.17	-0.1	0.84	-0.51	-0.6	0.8	0.62	0.78	0.82	0.75	0.79
Intangible Assets	0.6	0.05	0.34	0.63	0.7	0.11	0.35	0.05	-0.1	0.16		-0.22	0.06	-0.1	0.97	0.95	-0.97	0.37	0.18	0.27	-0.22	-0.25	-0.23	-0.22	-0.3	-0.26
Common Stock	0.47	0.85	0.7	0.41	0.05	0.29	0.54	0.68	-0.16	0.82	-0.22		0.76	0.55	-0.35	-0.13	0.35	0.73	-0.32	-0.83	0.79	0.58	0.99	1.0	0.91	0.76
Property Plant Equipment	0.37	0.7	0.61	0.33	0.32	0.31	0.89	0.29	-0.33	0.62	0.06	0.76		0.77	-0.14	0.17	0.14	0.81	-0.24	-0.87	0.36	0.08	0.74	0.78	0.78	0.35
Treasury Stock	0.03	0.52	0.34	0.01	0.01	-0.25	0.59	0.28	-0.19	0.25	-0.1	0.55	0.77		-0.31	-0.05	0.31	0.49	0.26	-0.76	0.13	0.05	0.57	0.57	0.59	0.15
Long Term Debt	0.56	-0.08	0.26	0.6	0.65	0.17	0.2	-0.03	-0.05	0.1	0.97	-0.35	-0.14	-0.31		0.88	-1.0	0.22	0.1	0.44	-0.23	-0.25	-0.36	-0.35	-0.43	-0.28
Good Will	0.57	0.13	0.32	0.6	0.69	0.07	0.37	0.09	-0.13	0.17	0.95	-0.13	0.17	-0.05	0.88		-0.88	0.43	0.21	0.16	-0.2	-0.22	-0.13	-0.13	-0.2	-0.24
Preferred Stock Total Equity	-0.56	0.08	-0.26	-0.6	-0.65	-0.17	-0.2	0.03	0.05	-0.1	-0.97	0.35	0.14	0.31	-1.0	-0.88		-0.22	-0.11	-0.44	0.23	0.25	0.36	0.35	0.43	0.28
Other Liab	0.8	0.66	0.74	0.78	0.53	0.42	0.78	0.62	-0.31	0.84	0.37	0.73	0.81	0.49	0.22	0.43	-0.22		-0.28	-0.66	0.62	0.25	0.68	0.75	0.72	0.58
Net Debt	-0.32	-0.15	-0.34	-0.29	-0.28	-0.96	-0.36	0.1	0.22	-0.51	0.18	-0.32	-0.24	0.26	0.1	0.21	-0.11	-0.28		0.24	-0.46	-0.09	-0.25	-0.33	-0.38	-0.49
Retained Earnings	-0.23	-0.71	-0.53	-0.18	-0.05	-0.2	-0.66	-0.41	0.41	-0.6	0.27	-0.83	-0.87	-0.76	0.44	0.16	-0.44	-0.66	0.24		-0.52	-0.31	-0.82	-0.85	-0.93	-0.52
Cash And Short Term Investments	0.63	0.51	0.54	0.59	0.09	0.41	0.18	0.82	-0.01	0.8	-0.22	0.79	0.36	0.13	-0.23	-0.2	0.23	0.62	-0.46	-0.52		0.63	0.74	0.79	0.77	0.97
Net Receivables	0.31	0.67	0.57	0.26	-0.08	0.02	-0.06	0.61	-0.16	0.62	-0.25	0.58	0.08	0.05	-0.25	-0.22	0.25	0.25	-0.09	-0.31	0.63		0.6	0.55	0.47	0.64
Common Stock Total Equity	0.41	0.88	0.7	0.36	0.02	0.22	0.52	0.66	-0.13	0.78	-0.23	0.99	0.74	0.57	-0.36	-0.13	0.36	0.68	-0.25	-0.82	0.74	0.6		0.99	0.88	0.71
Common Stock Shares Outstanding	0.47	0.84	0.69	0.41	0.06	0.3	0.56	0.67	-0.17	0.82	-0.22	1.0	0.78	0.57	-0.35	-0.13	0.35	0.75	-0.33	-0.85	0.79	0.55	0.99		0.92	0.76
Other Stockholder Equity	0.42	0.71	0.59	0.37	0.13	0.33	0.55	0.61	-0.29	0.75	-0.3	0.91	0.78	0.59	-0.43	-0.2	0.43	0.72	-0.38	-0.93	0.77	0.47	0.88	0.92		0.78
Total Current Assets	0.62	0.51	0.55	0.58	0.19	0.42	0.17	0.76	0.03	0.79	-0.26	0.76	0.35	0.15	-0.28	-0.24	0.28	0.58	-0.49	-0.52	0.97	0.64	0.71	0.76	0.78

Click cells to compare fundamentals

Enlivex Therapeutics Account Relationship Matchups

Enlivex Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	17.6M	40.4M	95.1M	67.6M	36.8M	30.6M
Other Current Liab	5.5M	3.7M	3.2M	4.0M	4.9M	5.1M
Total Current Liabilities	6.0M	4.4M	4.7M	6.6M	6.1M	3.6M
Total Stockholder Equity	11.3M	35.5M	85.0M	56.8M	30.1M	25.2M
Accounts Payable	316K	463K	878K	1.9M	827K	1.1M
Cash	3.9M	5.7M	11.2M	47.8M	926K	879.7K
Other Assets	72K	81K	0.0	412K	370.8K	259.0K
Short Term Investments	8.1M	30.0M	72.9M	299K	26.5M	27.8M
Other Current Assets	510K	32.4M	12.3M	2.4M	6.3M	6.3M
Total Liab	6.3M	4.9M	10.1M	10.8M	6.7M	5.5M
Common Stock	1.2M	1.6M	2.1M	2.1M	2.1M	2.2M
Property Plant Equipment	1.1M	2.1M	2.5M	14.9M	17.1M	18.0M
Net Debt	(3.8M)	(5.5M)	(10.6M)	(43.0M)	106K	111.3K
Retained Earnings	(25.7M)	(37.5M)	(52.0M)	(83.0M)	(112.1M)	(106.5M)
Cash And Short Term Investments	12.0M	35.7M	84.1M	48.1M	27.4M	23.0M
Net Receivables	2.4M	1.2M	2.2M	647K	744.1K	879K
Common Stock Shares Outstanding	8.6M	13.2M	17.9M	18.4M	18.6M	19.5M
Liabilities And Stockholders Equity	17.6M	40.4M	95.1M	67.6M	36.8M	31.4M
Other Stockholder Equity	37.1M	70.4M	133.8M	136.6M	138.9M	145.9M
Total Current Assets	16.4M	38.1M	86.4M	52.3M	33.8M	28.5M
Property Plant And Equipment Net	1.1M	2.1M	8.2M	14.9M	2.6M	3.3M
Non Current Assets Total	1.1M	2.2M	8.7M	15.3M	3.1M	3.2M
Non Currrent Assets Other	(329K)	8K	482K	105K	179K	188.0K
Property Plant And Equipment Gross	648K	2.1M	10.2M	18.4M	21.2M	22.3M
Non Current Liabilities Total	298K	499K	5.4M	4.2M	686K	651.7K
Net Tangible Assets	11.3M	35.5M	85.0M	56.8M	65.4M	32.8M
Net Invested Capital	11.3M	35.5M	85.0M	56.8M	65.4M	36.8M
Net Working Capital	10.4M	33.7M	81.7M	45.7M	52.6M	33.7M
Capital Stock	1.2M	1.6M	2.1M	2.1M	2.4M	1.7M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Enlivex Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Enlivex Therapeutics' short interest history, or implied volatility extrapolated from Enlivex Therapeutics options trading.

Pair Trading with Enlivex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enlivex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enlivex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Enlivex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enlivex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enlivex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enlivex Therapeutics to buy it.

The correlation of Enlivex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enlivex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enlivex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Enlivex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports:

How To Invest In Enlivex

Details

Is Enlivex Stock a good investment?

Details

What is Enlivex Therapeutics' Net Worth?

Details

Largest Application Software Companies

View

Largest Software & Services Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Enlivex Stock analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges

Is Enlivex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enlivex Therapeutics. If investors know Enlivex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enlivex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.47)

Return On Assets

(0.30)

Return On Equity

(0.67)

The market value of Enlivex Therapeutics is measured differently than its book value, which is the value of Enlivex that is recorded on the company's balance sheet. Investors also form their own opinion of Enlivex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enlivex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enlivex Therapeutics' market value can be influenced by many factors that don't directly affect Enlivex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enlivex Current Ratio vs Free Cash Flow per Share Analysis

Current Ratio vs Free Cash Flow Per Share

Current Ratio vs Free Cash Flow per Share Correlation Analysis

Correlation Coefficient

Current Ratio

Free Cash Flow Per Share

Enlivex Therapeutics fundamental ratios Correlations

Enlivex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enlivex Therapeutics fundamental ratios Accounts

Pair Trading with Enlivex Therapeutics

Complementary Tools for Enlivex Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Common Stock Shares Outstanding	+ 1.0	Common Stock
Common Stock Total Equity	+ 0.99	Common Stock
Common Stock Shares Outstanding	+ 0.99	Common Stock Total Equity
Long Term Debt	+ 0.97	Intangible Assets
Total Current Assets	+ 0.97	Cash And Short Term Investments

Preferred Stock Total Equity	- 1.0	Long Term Debt
Preferred Stock Total Equity	- 0.97	Intangible Assets
Net Debt	- 0.96	Cash
Other Stockholder Equity	- 0.93	Retained Earnings
Preferred Stock Total Equity	- 0.88	Good Will
Retained Earnings	- 0.87	Property Plant Equipment